Search
Turpentine
go.drugbank.com/drugs/DB11120ApprovedIt is used as a solvent and base material in organic synthesis reactions. … Turpentine, also known as spirit of turpentine, oil of turpentine, and wood turpentine, is a liquid extracted from live trees, mainly pine, through distillation of resin.
Categories: Compounds used in a research, industrial, or household setting, Complex MixturesProducts: Die Da Wan Hua Pain RelievingTralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalUS in December 2021. … While AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13).
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalIt works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival … Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexIpecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawnIpecac is obtained from the plant _Cephaelis ipecacuanha_ and contains a number of emetic alkaloids including emetine and cephaeline. … use to cause vomiting in poisoning.
Categories: Complex MixturesTipiracil
go.drugbank.com/drugs/DB09343ApprovedInvestigationalTipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. … The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism.
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, OCT2 Substrates with a Narrow Therapeutic IndexTrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigationalTrastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. … [A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]
Lerodalcibep
go.drugbank.com/drugs/DB19071ApprovedInvestigational[L54738] PCSK9 is a protein that binds to and promotes the degradation of low-density lipoprotein receptors (LDLRs), which are expressed on hepatocytes regulates circulating LDL levels. … Lerodalcibep is a recombinant fusion protein that binds to and inhibits proprotein convertase subtilisin kexin type 9 (PCSK9).
Formestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes. … Formestane is also a prohormone of 4-hydroxytestosterone, an active steroid with weak androgenic activity and mild aromatase inhibitor activity.
Synonyms: 4-OH-ATafenoquine
go.drugbank.com/drugs/DB06608ApprovedInvestigationalTafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.
Trihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. … [A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.
International brands: Ea Ten